Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCells's change in inventory for the quarter that ended in Jun. 2026 was NT$-9.95 Mil. It means DuoGenic StemCells's inventory
increased by NT$9.95 Mil
from Dec. 2025 to Jun. 2026 .
DuoGenic StemCells's change in inventory for the fiscal year that ended in Dec. 2025 was NT$2.01 Mil. It means DuoGenic StemCells's inventory
declined by NT$2.01 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
DuoGenic StemCells's Days Inventory for the quarter that ended in Jun. 2026 was 285.71.
Inventory Turnover measures how fast the company turns over its inventory within a year.
DuoGenic StemCells's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.64.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DuoGenic StemCells's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.71.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DuoGenic StemCells's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells Change In Inventory Related Terms
DuoGenic StemCells Change In Inventory Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of NT$-7.60 Mil mean?
DuoGenic StemCells (ROCO:7607) has a Change In Inventory of NT$-7.60 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for DuoGenic StemCells and its competitors.
Is DuoGenic StemCells' Change In Inventory too high?
DuoGenic StemCells' current Change In Inventory is NT$-7.60 Mil. Overall, DuoGenic StemCells has a GF Score™ of 30/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Change In Inventory compare to VRTX and REGN?
DuoGenic StemCells' Change In Inventory of NT$-7.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for DuoGenic StemCells and its competitors. DuoGenic StemCells's current Change In Inventory is NT$-7.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$27.99, compared to a current price of NT$11.85 — trading 57.7% below its estimated fair value. The current Change In Inventory is NT$-7.60 Mil. DuoGenic StemCells' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Change In Inventory is NT$-7.60 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$11.85 is trading 57.7% below its estimated GF Value™ of NT$27.99.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Change In Inventory: NT$-7.60 Mil
GF Value™: NT$27.99 vs. price of NT$11.85 (57.7% below fair value)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
30GF Score
Get the complete analysis for ROCO:7607
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
